Mauro, Michael J.

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 769

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Cortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 208

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

on behalf of the International CML Foundation Genomics Alliance, Branford, S., Kim, D. D. H., Apperley, J. F., Eide, C. A., Mustjoki, S., Ong, S. T., Nteliopoulos, G., Ernst, T., Chuah, C., et al. (2019) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 149

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL

Hochhaus, A., Réa, D., Boquimpani, C., Minami, Y., Cortes, J. E., Hughes, T. P., Apperley, J. F., Lomaia, E., Voloshin, S., Turkina, A., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 148

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 139

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Treatment‐free remission after dasatinib in patients with chronic myeloid leukaemia in chronic phase with deep molecular response: Final 5‐year analysis of DASFREE

Shah, N. P., García‐Gutiérrez, V., Jiménez‐Velasco, A., Larson, S. M., Saussele, S., Rea, D., Mahon, F., Levy, M. Y., Gómez‐Casares, M. T., Mauro, M. J., et al. (2023) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 29

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results

Hochhaus, A., Kim, D.-W., Cortes, J. E., Sasaki, K., Mauro, M. J., Hughes, T. P., Breccia, M., Talpaz, M., Minami, H., Goh, Y. T., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 14